Why Should You Attend:
In the recent past the US FDA has been criticized for its perceived failures in protecting the public from unsafe products. The widely publicized contaminated heparin use in medical products and drug failures such as Vioxxl have tarnished the image of FDA in its efforts to protect the public health. In response a new Commissioner was appointed with extensive experience in public health. She has rapidly changed FDA's response patterns to serious events.
The new FDA is working rapidly to improve its image with the public and with Congress in response to its perceived shortcomings over the past 20 years. This presentation will discuss how industry should interface with FDA in regard to anticipated recalls. Additionally we will discuss the potential response to the public in the event of a recall. The primary focus should be on providing a safe product and in the event of a failure to provide correct and complete information to protect the public health.